Predict your next investment

Metabolon company logo
Corporation
HEALTHCARE | Biotechnology
metabolon.com

See what CB Insights has to offer

Founded Year

2000

Stage

Debt - II | Alive

Total Raised

$183M

Last Raised

$50.23M | 10 mos ago

About Metabolon

Metabolon is a health technology company focused on metabolomics – a tool for precision medicine and life sciences research. The company's platforms and informatics deliver biomarker discoveries, diagnostic tests, and partnerships in genomics-based, health initiatives.

Metabolon Headquarter Location

617 Davis Dr Suite 100

Morrisville, North Carolina, 27560,

United States

+1 919 572 1711

Latest Metabolon News

The Top 50 Healthcare Technology CEOs Of 2021

Apr 14, 2021

. This year’s awardees represent some of the most accomplished executives in healthcare technology. Their leadership has been critical in developing industry leading medical devices, next generation software platforms, cutting-edge drugs and therapeutics, and advanced diagnostics, among other technologies. Notably, in addition to overseeing their companies’ efforts from the C-suite, many of these leaders were also founders or co-founders of their organizations, recognizing unique opportunities for transformation and growth within their areas of expertise. From inventing novel orthopedic and mobility devices, to spearheading platforms to strengthen the patient/provider connection, and to developing new blood tests to diagnose diseases, these awardees have made significant contributions to society at large. They come from varied backgrounds in medicine, research, biotechnology, business, and finance, leveraging unique insights to provide their companies with the agility and ingenuity needed to thrive. While highly involved and instrumental to the continued success of their companies, they have also remained dedicated to advancing their particular fields, with many participating in prestigious research institutions and trade groups that are collaborating to develop more effective solutions for patients across the globe. Please join us in honoring The Top 50 Healthcare Technology CEOs of 2021. Title: Chairman of the Board of Directors and Chief Executive Officer Geoff Martha is Chairman of the Board of Directors and Chief Executive Officer at Medtronic. He is firmly establishing Medtronic as the undisputed global leader in healthcare technology. As chairman and CEO, Martha leads the $30 billion company and its 90,000 employees in pursuit of fulfilling Medtronic’s mission to use technology to improve human welfare. He became CEO in April 2020. Under his leadership, Medtronic is putting the ‘tech’ in MedTech, leveraging the latest advances in technology to transform healthcare. Over the past year, Martha has accelerated Medtronic’s strategic acquisitions, and embraced new ways to partner across industries and global borders. Martha joined Medtronic in 2011, and notably led the acquisition and integration of Covidien, the largest acquisition in MedTech history. Prior to joining Medtronic, he was managing director of business development at GE Healthcare. He also held various roles at GE Capital, including general manager of GE Capital technology finance services. Martha serves on the board of directors for the Medtronic Foundation, Children’s HeartLink, and the Northside Achievement Zone. He is also part of OneTen, a coalition of cross-industry leaders committed to breaking down systemic barriers for Black Americans. He received his Bachelor of Science degree in finance from Pennsylvania State University. Title: President and Chief Executive Officer Marc Casper has been President and Chief Executive Officer of Thermo Fisher Scientific since October 2009. He was also elected chairman of the board in February 2020. Casper joined Thermo Electron Corporation in 2001 as president of the Life Sciences sector. He was named senior vice president in 2003, and in 2005 assumed responsibility for all of the company’s operating divisions. After the merger that created Thermo Fisher Scientific in 2006, he was named executive vice president and president of its Analytical Technologies businesses, and in 2008 he became the company’s chief operating officer. Prior to joining Thermo Fisher, Casper served as president, chief executive officer, and a director of Kendro Laboratory Products. Previously, he worked for clinical diagnostics provider Dade Behring Inc., serving as president–Americas. He began his career as a strategy consultant at Bain & Company and later joined Bain Capital. Casper serves on the boards of U.S. Bancorp, U.S. - China Business Council, Brigham and Women’s Hospital, and Wesleyan University. He was previously a director of the Advisory Board Company and Zimmer Holdings. Casper received a bachelor’s degree in economics from Wesleyan University and a Master of Business Administration degree with high distinction from Harvard Business School. Title: Chief Executive Officer and President Tom Polen is the Chief Executive Officer and President of BD, an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. Headquartered in Franklin Lakes, New Jersey, the company employs nearly 70,000 people in more than 50 countries throughout the world. Notably, BD was one of the first companies to sell U.S.-made glass syringes. Founded in 1897, it was also a pioneer in the production of hypodermic needles. Today, BD is divided into three segments: BD Medical, BD Life Sciences, and BD Interventional. In 2019 the powerhouse company was ranked #195 on the Fortune 500 list. Polen first joined BD in 1999 and has held a variety of leadership roles in numerous business units. He was appointed president of BD in April 2017, was named COO in October 2018, and became CEO in January 2020. Previously Polen worked at Baxter International Inc., where he was eventually promoted to general manager of Baxter’s Injectable Pharmaceuticals business. He earned his bachelor's degree from the Salisbury University of Maryland and a Master of Business Administration degree from Johns Hopkins University. Title: Chairman and Chief Executive Officer Mike Mussallem has served as Chair and Chief Executive Officer of Edwards Lifesciences since 2000. Under his leadership, Edwards has established its position as a global leader in structural heart and critical care monitoring with the introduction of lifesaving therapies such as transcatheter aortic valve replacement. During Mussallem’s tenure, he has not only led the development and successful implementation of the company’s patient-focused innovation strategy but also established Edwards’ commitment to philanthropy and corporate social responsibility. The Edwards Lifesciences Foundation and its Every Heartbeat Matters initiative has donated more than $100 million to support underserved patients globally and communities where Edwards’ employees live and work. Previously, Mussallem held a variety of positions at Baxter International from 1979 until 2000. Currently, Mussallem serves on the board of AdvaMed and is an advisory board member for the Leonard D. Schaeffer Center for Health Policy & Economics. He is a trustee of the University of California, Irvine Foundation and the Rose-Hulman Institute of Technology in Terre Haute, Indiana. Mussallem has served as board chairman of both AdvaMed and the California Healthcare Institute. Title: Chairman and Chief Executive Officer With over 30 years of healthcare sector experience and a proven track record driving value creation for multinational businesses, Chris Smith, Chairman and CEO of Ortho Clinical Diagnostics, has already made incredible strides for the company during his less-than-two-year tenure at the former J&J spinoff. Not only was he charged with leading one of the world’s largest pure-plays in vitro diagnostics (IVD) companies during the global COVID-19 pandemic, but he was also instrumental in taking the previously private equity-owned company public in January 2021. Upon Smith’s arrival in late 2019, he encouraged the team to look at the company’s product offerings and reinvest R&D dollars into strengthening the company’s product offerings and building out its pipeline. This investment has paid off as Ortho launched more than 75 new or improved assays in the past few years. Prior to joining Ortho, Smith served as the CEO of Cochlear Limited, a publicly-traded global medical device company headquartered in Australia. Under his leadership, Cochlear Limited reached annual sales in excess of AU $1 billion while the market cap of the company more than doubled. Prior to Cochlear, Smith held several senior executive roles, including CEO in residence for Warburg Pincus and global group president of Gyrus Group Plc., a surgical products company. Smith serves on the boards of directors of several companies, including Results Physiotherapy, Nyxoah, and Akouos, and was a senior external advisor for McKinsey & Co., AngelMD, and EQT Partners. He previously served on the boards of directors of publicly-listed Xtent Inc. as well as Startek Inc., Universal Biosensors, Gyrus Group Plc, and Acclarent Inc. Smith holds a Bachelor of Science degree from Texas A&M University. Title: Chief Executive Officer, President, and Chairman of the Board of Directors Kevin Sayer serves as the Chief Executive Officer, President, and Chairman of the Board of Directors of Dexcom, a medical device company that supplies the most common Continuous Glucose Monitoring (CGM) system in the world. Headquartered in San Diego, California, Dexcom also provides online analytics that allow the patient to review CGM data online and analyze it for patterns. Sayer's time at Dexcom certainly has not been without distinction. In 2015 he assumed the role of CEO where he currently has direct responsibility for all Dexcom strategy and operations. He's also served as the company's President since 2011, Chairman since 2018, Board member since 2007, and from 2013 until 2015 Sayer served as chief operating officer for the company. Prior to leading Dexcom, Sayer held various management positions, including at the medical technology company Biosensors, Specialty Laboratories, and Medtronic MiniMed. In addition, Sayer has spent years serving as an independent healthcare and medical technology industry consultant. He received both his Bachelor of Science degree and his Master of Science degree in accounting and information systems from Brigham Young University. Title: Chief Executive Officer and President, FACHE As Chief Executive Officer and President of Signature Healthcare since 2010, Kim Hollon has led this Southeast Massachusetts-based healthcare system to raise the bar in delivering safe, high-quality, patient-centered care. In his capacity at the head of Signature, Hollon oversees not only a not-for-profit hospital in Brockton, but also the Brockton Hospital School of Nursing and an ambulatory, multi-specialty group of providers known as Signature Medical Group. Hollon has consistently pushed for improved safety for patients, providers, and staff in all aspects of Signature’s culture, as well as securing improved financial stability and staff engagement. Hollon has devoted nearly four decades to effective hospital leadership, beginning his career as vice president of Baylor Health System before serving as president of Methodist Dallas Medical Center. Hollon subsequently oversaw four hospital campuses and a workforce of thousands as COO of Excela Health System. Hollon received his master’s degree in hospital administration from the University of Alabama at Birmingham. He is board certified in healthcare management as a fellow of the American College of Healthcare Executives. Title: President and Chief Executive Officer Rusty Frantz is the President and Chief Executive Officer of NextGen Healthcare. In this position, he spearheaded a five-year transformation that catapulted the company to achieve Best in KLAS rankings in dual ambulatory healthcare solution categories in 2020. NextGen Healthcare’s award-winning integrated care platform plays a vital role in strengthening the patient/provider connection, producing better outcomes for both – improved health for patients and more peace of mind for providers. The company celebrated another significant milestone in 2020, as more than 1 million patient visits were conducted via its telehealth solution. Authentic and accessible, Frantz has established a strong workplace culture, unified in its mission to empower the transformation of ambulatory care. Prior to NextGen Healthcare, Frantz was senior vice president and general manager of the global dispensing division of CareFusion. The transformational medication management strategy he developed across three of the company's global brands created $1 billion in global revenue and served as a key strategic driver in the acquisition of CareFusion by Becton Dickinson. Earlier in his career, Frantz stretched his entrepreneurial wings to co-found OutPurchase, a provider of cloud-based procurement solutions and services. Frantz received his Bachelor of Science degree in marine engineering from the Maine Maritime Academy and his Master of Science degree in computer engineering from Stanford University. Title: Chief Executive Officer, Chairman, President, and Founder Randall Lipps is the Chief Executive Officer, Chairman, President, and Founder of Omnicell, a leading provider of technological solutions designed to increase both patient safety and operational efficiency in a wide range of health care facilities. Since its launch in 1992, the company has achieved substantial growth. Today over 7,000 facilities worldwide use Omnicell automation and analytics solutions to improve the patient experience in multiple ways. Under the visionary leadership of Lipps, Omnicell has grown from offering a single product to delivering award-winning solutions in over 40,000 institutional and retail pharmacies across the world. Lipps founded Omnicell in 1992 after observing how inefficiently medical supplies were managed when his daughter was hospitalized at birth. Before that, Lipps was the assistant vice president of sales and operations for a division of American Airlines. Lipps is also a member of the Board of Trustees of the American Nurses Foundation, and serves as the director at large of the American Society of Health-System Pharmacists Foundation's Board of Directors. In 2014, Lipps was elected to the Bellwether League Hall of Fame. He received bachelor's degrees in both economics and business administration from Southern Methodist University. Title: Chief Executive Officer Chris Barry is the Chief Executive Officer of NuVasive, the largest spine-focused technology company. Since his appointment in 2018, Barry has set a clear, long-term strategy and built the strongest innovation pipeline in the global spine market focused on advancing less invasive surgery. With his guidance, NuVasive has implemented a long-term diversity and inclusion roadmap to foster an inclusive workplace and enhance diversity within the organization, including the creation of Women in Spine—a women-led, employee resource group. Prior to his role as CEO of NuVasive, Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue. Prior to the acquisition of Covidien by Medtronic, Barry was president of advanced surgical technologies at Covidien, where he led global strategy, product portfolio, and U.S. commercial teams for the $3.2 billion global business unit. He spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Barry is currently a board member on the NuVasive Board of Directors and the Medical Device Manufacturers Association. He received his Bachelor of Science degree in environmental science from Texas Tech University. Title: President and Chief Executive Officer Life science cloud software juggernaut ArisGlobal has been helmed by President and Chief Executive Officer Sankesh Abbhi since 2017. Under Abbhi’s vision and guidance, ArisGlobal leads the field in building intelligent applications that are transforming life sciences R&D. With its LifeSphere® platform, ArisGlobal has revolutionized how organizations develop and bring drugs to market with ever-greater efficiency and accuracy, thanks to investments in artificial intelligence and cognitive computing. Before being named President and CEO, Abbhi worked as managing director for global delivery, product strategy, and business excellence at ArisGlobal. Abbhi launched his career by founding Miami-based knowledge outsourcing process startup Synowledge—this firm was later acquired by Bioclinica, where Abbhi subsequently worked as managing director and senior vice president of global safety and regulatory solutions. Abbhi received his Bachelor of Arts degree in economics from Columbia University. Title: Chief Executive Officer and Co-Founder Helmy Eltoukhy is the Chief Executive Officer and Co-Founder of Guardant Health, a precision oncology company focused on the global cancer crises. Founded in 2012, the company provides proprietary blood tests, data sets, and analytics that help fight cancer. One of its main products, Guardant360, a liquid biopsy for advanced solid tumor cancers, has been used more than 150,000 times since it came out in 2014. In early 2021, Guardant reported that its fourth quarter 2020 revenues rose 25 percent year over year, driven by an increase in clinical testing volumes and revenue. In the healthcare sector, Eltoukhy is well-known for not only being Guardant's wildly successful CEO, but also for his many contributions to genomics, semiconductor DNA sequencing, and personalized medicine. Before Guardant, he was cutting his entrepreneur teeth as the co-founder of Avantome, which was acquired by Illumina in 2008. Eltoukhy received his Bachelor of Science degree, Master of Science degree, and Doctor of Philosophy degree in electrical engineering from Stanford University. Title: Chief Executive Officer, President, and Director John Sheridan is the Chief Executive Officer, President, and Director of Tandem Diabetes Care, a publicly traded company that develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy. In 2008, Tandem was launched with a focus on promoting a comprehensive, user-centric, and integrated approach to diabetes product development and customer care. Unlike its predecessors, Tandem felt it was important for its device to be both easy to use and aesthetically appealing. The idea was a success. Sheridan’s first roles at Tandem came when he joined the company as a chief operating officer and executive vice president in 2013. Six years later, in 2019, he was on the board of directors, while also serving as President and CEO, where he's been leading growth in sales and development of new healthcare technologies. Prior to Tandem, Sheridan worked in numerous management positions for several different companies in the medical technology sector, including Volcano Corporation, CardioNet, and Digirad Corporation. Sheridan first received his Bachelor of Science degree in chemistry from the University of West Florida before earning his Master of Business Administration degree from Boston University. Title: Chief Executive Officer Michele Antonelli is the Chief Executive Officer of Stallergenes Greer, a global biopharmaceutical company that specializes in the diagnosis and treatment of respiratory allergies through immunotherapy. Stallergenes Greer’s portfolio of treatment solutions is tailored to each patient profile, and to each market. This may include: injectable therapies, sublingual therapies such as drops and tablets, venoms, and also diagnostics. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). As CEO, Antonelli is the very definition of a seasoned biopharmaceutical executive. When he first joined Stallergenes Greer in 2015, he brought more than 20 years of extensive international experience in the biopharmaceutical industry. Prior to Stallergenes Greer, Antonelli worked at UCB, the multinational biopharmaceutical company, where he held roles of various responsibility and scope in Belgium, Italy, and France. Prior to joining UCB, Antonelli spent 16 years at Merck Serono, ultimately serving as senior vice president and global head of biotech manufacturing and process development. Antonelli graduated as a Doctor in Sciences from the University of Bari. He trained in biotechnology at Catholic University in Piacenza and at Iowa State University. Title: Chairman and Chief Executive Officer Chairman and Chief Executive Officer Brent Lang has transformed Vocera Communications into a force for innovation in global healthcare markets. Lang first joined Vocera when it was only a startup nearly two decades ago, passing through the ranks of vice president and COO before taking up his current role in 2013. Under Lang’s stewardship Vocera has grown into a titan in the worlds of clinical communications and workflow solutions, generating revenues of roughly $200 million last year and a market capitalization representing more than $1.2 billion. Apart from his nearly two decades of steering Vocera to new heights in various leadership positions, Lang also worked as a senior director at computer networking firm 3Com. In addition to numerous professional publications and honors from academic and entrepreneurship entities, Lang is an active volunteer, serving on the leadership council of the Positive Coaching Alliance and as independent director for U.S.A. Gymnastics. Lang received his Bachelor of Science degree in industrial and operations engineering from the University of Michigan and his Master of Business Administration degree from the Stanford University Graduate School of Business. Lang was a member of the 1988 U.S. Olympic Swimming Team and won a Gold Medal in the 4X100 Freestyle Relay at the Summer Olympics in Seoul, South Korea. Title: Chief Executive Officer Nancy Ham is the Chief Executive Officer of WebPT, the country’s leading outpatient therapy software platform for enhancing patient care and fueling business growth. Since joining WebPT in 2016, Ham has led WebPT through major achievements including reaching 40 percent market share, launching several new product innovations, executing two significant acquisitions, and securing backing from Warburg Pincus––one of the world’s top private equity firms. Prior to joining WebPT, Ham was the CEO of Healthagen Population Health Solutions, an Aetna company, as well as MedVentive, later acquired by McKesson. Her experience also includes executive roles at notable healthcare innovators, including Sentillion, ProxyMed, and Healtheon/WebMD. As a result of Ham’s passion for promoting innovation in healthcare, she has been twice honored by Health Data Management as one of the 25 Most Powerful Women Thought Leaders in Health IT, was named as one of the Top 25 Women in PE-Backed Software Companies by The Lancer Group, and was a finalist for EY’s Entrepreneur of the Year in 2020. Ham also serves in several board and advisory roles, including Blue Cross Blue Shield of Arizona, Arizona Commerce Authority, and HLM Venture Capital. She received her Bachelor of Arts degree in economics from Duke University and her Master of International Business degree in international business from The University of South Carolina. Title: Chief Executive Officer and Co-Founder David Medvedeff is the Chief Executive Officer and Co-Founder of Aspen RxHealth, a company disrupting the pharmacy profession by crowd sourcing passionate pharmacists around the nation to deliver clinical patient care on behalf of payers and providers. As the leader in next-generation clinical pharmacy services, Aspen RxHealth intelligently matches pharmacists with patients based on often overlooked social and clinical factors to enrich the patient-pharmacist experience and drive better outcomes for health plans and other risk-bearing providers. Since launching Aspen RxHealth in 2018, Medvedeff and his team have built the largest community of more than 5,000 pharmacists across the nation, empowering patients with the information and action plans they need to achieve optimal health outcomes. Prior to starting Aspen RxHealth, Medvedeff served as president and CEO of several successful healthcare companies including Gold Standard (acquired by Reed Elsevier), Avatar International (acquired by Press Ganey Associates), and VUCA Health, where he is an Executive Chairperson. His professional accomplishments have been recognized with numerous accolades including the National Prescott Award, the Next Generation Pharmacist Technology Innovator, and he is the only two-time winner of the American Pharmacists Association Foundation’s Pinnacle Award. Medvedeff studied organic chemistry at the University of Florida, where he earned his Doctor of Pharmacy and Master of Business Administration degrees. He has served on the faculty of the College of Pharmacy as an Associate Professor and has received the Outstanding Alumnus and the Outstanding Service Awards from the College. Title: President and Chief Executive Officer Philip Settimi, MSE, M.D., serves as President and Chief Executive Officer for Ohio-based PartsSource, whose pioneering evidence-based supply chain software platform and vertical marketplace serving mission-critical healthcare operations has been adopted at over 3,500 hospitals and 15,000 clinical sites worldwide. Under Dr. Settimi’s leadership since 2014, PartsSource has developed the industry’s first Clinical Resource Management platform that uses patented algorithms and 3 billion data elements to maximize the safety, reliability, productivity, and cost-effectiveness of the medical device supply chain. During this time, PartsSource has earned ISO 9001 and 13485 certification, and extended improvement insights on product quality, logistics, and customer experience to thousands of suppliers and OEMs in the healthcare ecosystem. PartsSource’s growth and financial results are similarly impressive, and the firm was acquired to great acclaim by Great Hill Partners in 2017. Dr. Settimi has also served as a member or advisor to numerous boards of healthcare technology entities, and as an operating executive to multiple leading private equity firms. He has held diverse leadership positions in public medical device and HCIT companies including Hillrom, Hospira, and GE Healthcare, and he holds numerous patents related EMR-usage to enroll and conduct clinical studies in medicine. Dr. Settimi received his Bachelor of Arts degree in economics as well as a master’s degree in biomedical engineering and a Doctor of Medicine degree, all from the University of Michigan. Title: Founder and Chief Executive Officer Andrew Parker founded digital healthcare startup Papa in 2017, and still leads the company as Chief Executive Officer. Leveraging his expertise in technology and distance healthcare services, Papa was designed by Parker to fill a need he perceived in his own life: difficulty among seniors in getting basic social, health, and technology needs met. Papa was launched to match independent companions with seniors in need, and has since built critical partnerships with health insurance firms and Medicare providers. When confronted with the COVID-19 pandemic Parker worked to transform Papa yet again, providing virtual companionship to its members while adhering to social distancing guidelines. Parker draws on considerable professional experience in technology and healthcare. After working as an account executive for Cbeyond (later acquired by Birch), he was an account manager for AT&T before leaving to work for Florida-based digital healthcare platform MDLIVE. There Parker rose from director of sales to eventually serve as vice president of health systems for three years. Parker earned his Bachelor of Science degree in finance from Florida State University and went through Y-Combinator’s prestigious incubator. Title: President and Chief Executive Officer President and Chief Executive Officer since 2018, Rohan Hastie has helped usher North Carolina-based firm Metabolon into a new era of success in the fields of precision medicine and clinical metabolomics. Hastie has contributed his vision to directing the company’s exclusive Precision Metabolomics Platform to turn cutting-edge biological insights into medical breakthroughs. With more than 5,000 proprietary metabolites and 10,000 completed projects to its name, Metabolon is leading the charge in bringing together diverse fields such as biopharmaceuticals, academic research, and consumer products to improve our understanding of health. Hastie brings considerable experience in the sciences and healthcare industries to bear on his work with Metabolon. Having previously served as president of Arrow Life Sciences & Healthcare, Hastie served in several executive roles for Hologic, Inc. for more than eight years, building the company into an industry leader in cancer screening and molecular diagnostics. Hastie received his Bachelor of Science degree in biological sciences from the University of Birmingham and holds a Ph.D. in molecular genetics from Queen Elizabeth Medical School in Birmingham, UK. Title: Co-Founder and Chief Executive Officer An accomplished entrepreneur and former physician, Florian Otto now drives growth and sets overall direction across all facets of Cedar’s operations. Compelled by a personal bad experience with healthcare billing, combined with background in both the clinical and business sides of healthcare, Otto founded Cedar in 2016 with his co-founder, Arel Lidow, to address the poor financial experience commonly seen in healthcare and improve this experience for patients. Prior to founding Cedar, Otto was an executive at Zocdoc and also founded a daily deal company in Brazil (ClubeUrbano) that was eventually acquired by Groupon. After the acquisition, he became chief executive officer of Groupon Brazil, growing the company to one of Groupon’s top three international markets. Otto began his business career as a strategy consultant at McKinsey & Company within their healthcare practice. Otto holds Doctor of Medicine, Doctor of Dental Surgery, and PhD degrees from the University of Freiburg, Germany. Title: Co-founder and CEO Carl Hansen, Ph.D. is an entrepreneurial scientist working at the interface of engineering, biology, and computation. He is the Co-founder and CEO of AbCellera, a technology company that partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. In partnership with Eli Lilly and Company, AbCellera discovered and co-developed the first monoclonal antibody, specifically developed against SARS-CoV-2, to receive Emergency Use Authorization from the U.S. Food and Drug Administration. Bamlanivimab alone and together with etesevimab are authorized under special/emergency pathways, in the context of the pandemic, in the U.S. and the European Union. Bamlanivimab alone is authorized for emergency use in 15 countries. In addition to AbCellera, Hansen co-founded Precision Nanosystems, which develops next-generation delivery technology for genetic medicines. Hansen’s work includes 90 peer-reviewed manuscripts and abstracts, 75+ patent applications, and eight commercial products. Hansen and the AbCellera team have enabled 100+ drug development efforts being pursued by leading biotech and pharmaceutical companies around the world. Title: Chief Executive Officer Deborah Kobewka is the Chief Executive Officer of Evaluate Ltd., a company that has been providing predictive analytics for the pharmaceutical and medical device industries for 25 years. Using an online subscription model, customers of Evaluate can view future predictions of the global pharmaceutical market in a single, standardized platform. In 2020, the company released its most recent product, Evaluate Omnium. By applying proprietary methodologies and machine learning algorithms to 6 million data points and 26,000 R&D programs, Evaluate Omnium has already shown that it can deliver significant increases in accuracy when predicting which Phase I drugs will reach the market, and the commercial return of Phase I drugs. Kobewka has led Evaluate since March of 2019. As a leader, she is known for her dynamic style that has produced a successful track record of driving commercial expansion in the global pharmaceutical, healthcare, and information sectors. Kobewka joined Evaluate from a government role, having served as the managing director of Healthcare U.K. at the U.K.’s Department for International Trade. She received her Bachelor of Science degree in biochemistry from the University of Sussex. She also completed the Accelerated Development Program at the London Business School. Title: President and Chief Executive Officer As President and Chief Executive Officer of Canadian healthcare tech firm Christie Innomed, Martin Roy has led this longtime industry titan into a new era of success over the past five years. Among Christie Innomed’s recent achievements are its innovations in the fields of systems architecture, application development and related technology, and radiology to optimize the patient and healthcare worker experience. Roy has also championed Christie Innomed’s strategic partnership with other Canadian healthcare entities, including the Institut de Cardiologie de Montréal and Medical Devices Canada, bringing new solutions for transformative patient care to the front lines of healthcare. Before rising high in the field of healthcare technology, Roy spent more than a decade in sales and marketing. After serving as director of business development and director of sales marketing for Montreal’s BMO Financial Group and Lyreco, respectively, Roy worked for nearly ten years with McKesson, helping the pharmaceutical division of the Canadian healthcare giant consistently outperform market growth. Roy received his bachelor’s degree in business administration and management from Université du Québec à Montréal. Title: Founder and Chief Executive Officer As Founder and Chief Executive Officer of Precision Medical Products (PMP), Jeremy Perkins has built this small startup into a force to be reckoned with in the field of medical products for consumers and healthcare providers. Specializing in orthopedics, spinal devices, and podiatry for hospital accounts, PMP now employs sales and medical specialists in more than 40 states. PMP has been consistently recognized for its successes, ranked as the top fastest growing company in the Sacramento region by the Sacramento Business Journal in 2014, as well as receiving an award for innovation in 2018. Before he launched PMP in 2010, Perkins accumulated a reputation for excellence in sales and marketing. After serving as district sales manager for Southwestern, managing more than 60 sales representatives, Perkins’s career carried him into medical products in the position of senior territory sales manager for DonJoy Orthopedic. Perkins received his bachelor’s degree in industrial technologies from California Polytechnic State University in San Luis Obispo. Title: Chief Executive Officer and Founder Brian Ward is the Chief Executive Officer and Founder of Aroa Biosurgery, a soft tissue repair company which helps doctors and surgeons heal complex wounds. The New Zealand-headquartered firm is quickly emerging as a global leader in tissue regeneration. Aroa’s expertise lies in medical device development for soft tissue reinforcement and cellular scaffolding. Clinically proven with peer reviewed publications, all five of Aroa's current products use its Endoform technology, which utilizes part of a sheep's stomach as a scaffold to encourage cell regeneration and wound healing. Since its launch in 2008, the Aroa platform has already been used in over four million procedures targeting such areas as chronic wounds, hernia, soft tissue, and breast reconstruction. In addition to his daily CEO responsibilities, he has also been a director of Aroa Biosurgery since September 2007. He has extensive management experience in life sciences companies, having worked for a number of multinationals such as Baxter, Beecham, and SmithKline Beecham. On top of that, Ward has sat on a number of government and industry expert panels. He received his Bachelor of Science degree in veterinary science from Massey University and also holds a Master of Business Administration degree. Title: Founder and Chief Executive Officer Dr. Mohamed Shoura, PhD is the Founder and Chief Executive Officer of PaxeraHealth Corp., a Boston-based healthcare imaging software platform company that provides cutting-edge products built to combat the industry’s most significant challenges. As a global company with operations in six territories, PaxeraHealth provides a full suite of comprehensive imaging solutions and professional services to clients across the globe, including solutions for enterprise imaging, vendor neutral archive, image sharing, and mobile imaging applications. Dr. Shoura’s commitment to understanding client needs and delivering outstanding results through innovative solutions is just one reason the company continues to flourish today. His contribution to AI technology in imaging has had an immense effect on the advancement of the scoring and labeling of imaging studies. Before PaxeraHealth’s launch in 2009, Dr. Shoura spent years honing his technology, leadership, and entrepreneurial skills at industry giants Siemens and Toshiba Medical Systems, in addition to earning his PhD in medical imaging. In 2016, he founded the award-winning CarePassport platform with the goal of continuing to change healthcare by empowering patients to take a more active role in their care and advancing health service efficiency. Dr. Shoura is a true innovator and while his companies’ solutions have earned him many accolades, such as PaxeraHealth’s Best in KLAS awards for Global PACS in 2020 and 2021, as well as CarePassport’s Frost & Sullivan Innovation Award in 2018, it is his passion and vision to transform the medical imaging industry that makes him most celebrated as a leader. Title: Chairman and Chief Executive Officer Dr. Lishan Aklog is Chairman and Chief Executive Officer of PAVmed Inc., a commercial stage multi-product medical technology company which he co-founded based on a portfolio of his own innovations, including in carpal tunnel syndrome and infusion therapy. He is also Executive Chairman of its major subsidiary, Lucid Diagnostics Inc., which markets the only commercially available tools for early precancer detection to prevent esophageal cancer in patients with chronic heartburn. He previously co-founded Pavilion Holdings Group which created four medical device companies, including Vortex Medical which developed and commercialized his life-saving invention AngioVac®. Prior to entering the life sciences industry, Dr. Aklog had a distinguished academic and clinical career as a technological innovator in cardiac surgery serving on the faculty of leading institutions including Harvard Medical School and the Mount Sinai School of Medicine. He also serves on the board of directors of two life sciences companies, and the leading medical technology trade association, AdvaMed. Dr. Aklog, who fled political violence in Ethiopia as a young teenager, has been active in philanthropic organizations, including as a member of the international board of directors of Human Rights Watch. He received his Bachelor of Arts degree in physics from Harvard University and his Doctor of Medicine degree from Harvard Medical School. Title: Chief Executive Officer Eliane Schutte has been the Chief Executive Officer of Xeltis since 2018. Under her leadership, the company expanded its strategy to cover valve and vascular applications. She initially joined Xeltis in 2015 as chief development officer, leading its clinical trial program, product development strategy, and regulatory functions. Xeltis is a clinical-stage medical device company with the world’s first polymer-based technology platform designed to enable natural restoration of heart valves and blood vessels in the body. The technology uses a patient’s own natural healing system to develop a new living functional vascular graft or heart valve. The novel technology is comprised of supramolecular polymers (a Nobel-prize awarded discovery) and uses electrospinning manufacturing methods to create a unique architecture of small diameter vascular grafts and heart valve implants. Schutte has extensive expertise in global product development and regulatory affairs in medical devices, with over 20 years of experience in the biotech industry. Prior to Xeltis, she was vice president for global product development in peri-operative care at The Medicines Company. She was previously chief development officer at ProFibrix, a Dutch-U.S. biotech start-up acquired by The Medicines Company and vice president for regulatory affairs and EU operations at IsoTis Orthobiologics. Title: Chief Executive Officer Under the leadership of Chief Executive Officer Megan Bailey, Personal Genome Diagnostics (PGDx) developed and implemented a strategy to transform cancer care by delivering comprehensive genomic testing into the local setting, enabling greater access to precision medicine for healthcare systems, laboratories, and patients worldwide. The PGDx portfolio of tissue-based and liquid biopsy products is designed to inform treatment decisions for patients battling cancer by identifying what is driving the cancer at the molecular level. Bailey and Personal Genome Diagnostics also partner with biotech and pharmaceutical companies so PGDx’s leading cancer genomics platform can be used to accelerate the development of biomarker driven therapies. By empowering researchers, clinicians, and pharmaceutical partners, Bailey believes the PGDx mission of empowering the fight against cancer is brought to life on a daily basis. Bailey has more than 18 years of leadership experience in the healthcare industry. Bailey joined PGDx in March 2018 as the vice president of marketing. In late 2019, she was promoted to chief commercial officer where she led the company’s marketing, sales, and customer support teams, and in April 2020, she was appointed Chief Executive Officer and a member of the PGDx Board of Directors. Prior to PGDx, she held several commercial leadership roles of increasing responsibility for Roche Diagnostics. In addition to her passion for impacting cancer care, Bailey currently serves on the University of Maryland Baltimore Foundation Board of Trustees as an advocate and advisor for the Foundation’s philanthropic efforts aimed at enhancing the University’s educational, research, clinical, and service missions. Bailey received her Bachelor of Science degree from the United States Military Academy at West Point and her Master of Public Health degree in administration from the University of North Carolina at Chapel Hill. Title: President and Chief Executive Officer Tiffany Wilson, a longtime leader in the fields of business strategy and medical technology, currently holds the position of President and Chief Executive Officer of the University City Science Center in Philadelphia. With more than two decades of experience in bringing advances in medical technology to the worlds of business and education, Wilson is at the forefront of building Science Center into a regional center of innovation and education. Science Center currently manages more than a dozen programs to foster equity and access within STEM fields while fostering the latest advances in the worlds of medicine and medical technology. As Wilson’s current post reflects, her career has been built on varied experiences at the intersection of science and business. Wilson has also contributed her expertise to the boards of numerous science and medicine related organizations, including Southeast Life Sciences, Georgia Bio, Sanara Ventures, and the United States Department of Commerce’s National Advisory Council on Innovation and Entrepreneurship. Wilson received her Bachelor of Business Administration degree in international business from Loyola University and her Master of Business Administration degree from Georgetown University’s McDonough School of Business. Title: Co-Founder and Chief Executive Officer As Co-Founder and Chief Executive Officer of Patientco, Bird Blitch has devoted his efforts to developing reliable patient-focused healthcare payment tools. Blitch co-founded Patientco in 2009 to fill a substantial gap within the healthcare experience, helping providers administer a simple, seamless experience that can easily be navigated by their patients when making payments or resolving financial issues. Since then, he has steered Patientco into its place as a disruptive force within the healthcare industry, advancing patient-focused platforms and empowering providers to improve their relations with their customers through enhanced medical billing and payment technology. Blitch’s achievements in streamlining the patient experience within healthcare are a natural outgrowth of his considerable experience in other tech enterprises. Before co-founding Patientco, Blitch worked for more than a decade as CEO and executive vice president of Calero Software (formerly BroadSource). Blitch is an avid volunteer within his chosen industry, serving as chairman of the HIMSS revenue cycle improvement task force as well as the ATDC board of advisors and as chair of the board of trustees for the Georgia Institute of Technology. Blitch received his Bachelor of Science degree in industrial engineering from the Georgia Institute of Technology. Title: Chief Executive Officer and Co-Founder Leveraging his considerable expertise in the world of finance, Kent Ivanoff co-founded patient financial engagement platform VisitPay in 2010 and currently leads the firm as Chief Executive Officer. VisitPay was designed to revolutionize the patient payment experience, increasing both patient loyalty and financial results for healthcare providers while streamlining the payment process from end to end. Since then, VisitPay has expanded to serve millions of patients for enterprise health systems with almost $100 billion in net patient revenue. Ivanoff has a great deal of experience in the world of finance, having worked in an executive vice presidential role at Capital One Financial for nearly a decade and co-founding credit card origination and servicing startup American Direct Credit, which Capital One later acquired. Outside his current role as CEO of VisitPay, Ivanoff has served on the boards of Cambia Health Solutions and transformative, tuition-free high school One Stone. Ivanoff received his Bachelor of Science degree in chemical engineering from the University of Idaho and his Master of Business Administration degree in finance and general management from the Stanford University Graduate School of Business. Title: Chief Executive Officer Mark Casner is the Chief Executive Officer of Providence Anesthesiology Associates, an independent medical firm that specializes in providing anesthesia and perioperative care across a growing list of hospitals and healthcare facilities in the states of North and South Carolina. Since being launched in 1991, the company’s workforce has grown to more than 100 anesthesiologists as well as a number of nurse anesthetists (CRNA), nurse practitioners, and physician assistants. Among their main goals, Providence physicians use their vast array of expertise to help stem the tide of opioid abuse, minimize healthcare costs, and improve the overall patient experience for more than 150,000 patients each year. When it comes to making healthcare companies successful, Casner is an expert with more than three decades of experience in the field. As an executive, Casner has achieved extraordinary success in business turnaround, market expansion, and competitive positioning. Previously, Casner was the vice president of operations at CRH Medical Corporation, and spent nearly six years as chief executive officer at Aisthesis, formerly Safe Sedation. Before that Casner held executive positions in Digirad Corporation, DMS Imaging, Radiologix Inc., and Community Radiology Associates. He received his Bachelor of Arts degree in psychology from Miami University, a Master of Arts degree in human development from the University of Maryland, and a Master of Business Administration degree from Marymount University. Title: Chief Executive Officer and Director Scott Durbin is the Chief Executive Officer and Director of Viveve. He joined Viveve in early 2013 and was promoted to his current role in May 2018. He previously served as the company’s chief financial officer and has been instrumental in the company’s growth. He is committed to leading the company and the clinical and commercial development of its innovative CMRF technology to solidify its position as a global leader in women’s intimate health. Durbin’s 25-year career in the life sciences industry covers corporate finance, strategy, clinical, and operational experience – a unique combination of science and finance skills. Prior to joining Viveve, he was chief financial officer of Aastrom Biosciences, a publicly traded, cardiovascular cell therapy company. Before Aastrom, he spent six years as chief operating and financial officer for Prescient Medical, Inc. (PMI). He began his career in corporate finance as an investment banker in the healthcare and M&A groups at Lehman Brothers Inc., where he focused on mergers and acquisitions and financings for the life sciences industry. Durbin received his Bachelor of Science degree in biopsychology/pre-med from the University of Michigan and a Master of Public Health degree in health management from Yale University. Title: Founder, President and Chief Executive Officer Randy Boldyga is the President and CEO of RXNT, a cloud-based healthcare software company in Maryland. Boldyga founded RXNT in 1999 with a vision to create a better, safer way to prescribe medications. Along with a small team, he started the e-prescribing company and it has been privately-owned and operated ever since, with no venture capital. Today, RXNT provides the ambulatory care market with a fully-integrated suite of proven solutions that includes electronic medical records, medical billing, practice management, patient scheduling, and e-prescribing. Under Boldyga’s guidance, RXNT has become a leader in the Health IT market, with thousands of providers of all sizes and specialties trusting the system to keep their practice running smoothly. Before founding RXNT, Boldyga led IT operations at The Columbia Bank in Maryland. Prior to that he managed the Clinical Health Information Systems Department at the University of Arkansas Medical Sciences (UAMS), where he learned first-hand the technology challenges faced by medical teams at the point-of-care. Boldyga has also worked as an information technology consultant for the Department of Defense, the Department of Energy, and the Federal Bureau of Investigation. He received a Bachelor of Science degree in mathematics from the University of Maryland, Baltimore County. Title: Chief Executive Officer and Founder Richard Uhlig is the Chief Executive Officer and Founder of Quadrant Biosciences, an award-winning life sciences lab that is based in Syracuse, New York. By leveraging the power of artificial intelligence and machine learning, Quadrant uses algorithms, based on large data sets, to discern trends. The company developed the Clarifi testing platform, which can be used to detect diseases and disorders, including traumatic brain injury, autism spectrum disorder, and even COVID-19. Recently the company has hit many milestones, including developing the world's first saliva based epigenetic test for autism spectrum disorder. While in 2020, sales from their new saliva COVID-19 tests exceeded $6.5 million. Uhlig spent years on Wall Street before taking on a new path as the CEO of Quadrant. Previously, he was head of liquidity risk at the Federal Reserve Bank of New York. Before that he was the chairman and CEO of Morgan Stanley Bank, the principal banking subsidiary of Morgan Stanley, and was the chief investment officer at Merrill Lynch Bank. He held other significant posts in the financial industry and served as an executive in residence at Cornell University’s Johnson Graduate School of Management. Uhlig received his bachelor’s degree from Cornell University. Title: Chief Executive Officer and Co-Founder Amir Abolfathi is the Chief Executive Officer and Co-Founder of uLab Systems, Inc., a company that develops a suite of products for orthodontic tools. These tools include the next generation uSmile system, which gives orthodontists control over treatment planning and processes while reducing their lab costs. Based in San Mateo, California, uLab Systems recently received clearance from Health Canada to provide uSmile Clear Aligners and uDesign® treatment planning software to Canadian orthodontists. The products will be available country-wide in the last half of April 2021. As CEO of the company, Abolfathi has over 30 years of experience founding, building, and managing medical device companies. Prior to uLab, Abolfathi was a founding member of Tusker Medical, which was acquired by Smith & Nephew in 2020. Abolfathi has also held various management and engineering positions at Sonitus Medical, Inc., Align Technology Inc., Pfizer, Guidant, and Baxter. As a seasoned entrepreneur, he has over 60 issued and pending patent applications, including 11 publications in peer reviewed journals. Abolfathi received his Bachelor of Science degree in biomedical engineering from the University of California San Diego, before earning a Master of Science degree in management from the University of Southern California two years later. Title: Chief Executive Officer and Founder CEO of Catalyst Healthcare and Founder of Pack4U, Shane Bishop transitioned from the business of owning and operating automated pharmacies to leading and developing a scalable ecosystem of connected technologies to ensure that medications are taken on time, exactly as prescribed. As a pharmacist and entrepreneur, Bishop has consistently raised the bar for healthcare innovation and patient care models. He started Glenpark IDA Pharmacy in 1996, an independent pharmacy that served retail patients and long-term care facilities. In 2003, he established the first two high volume central-fill pharmacies in Western Canada. He holds a technology patent enabling AdhereNet® and is the author of centralized filling and checking legislation for the province of British Columbia. A trusted consultant and champion of medication safety, he was the Advisory Committee Chair for Healthy Residential Solutions Inc (HRS) in 2009, leading an independent pharmacy collaboration that used technology, including Catalyst's AdhereNet® pharmacy software platform and electronic medication administration record, oneMAR®, to ensure quality patient care. Today, the companies he leads collaborate with organizations globally to improve health outcomes at scale and lower total cost of care with in-home medication delivery and remote patient monitoring. Title: Chief Executive Officer and Co-Founder Jim Flatt is the Chief Executive Officer and Co-Founder of Brightseed, a fast-growing biotechnology company that is using A.I. to fortify our food with miracle ingredients found in plants. Not unlike the way Google indexed the Internet, Brightseed is in the early stages of indexing the plant kingdom's molecular structures in order to uncover previously unknown compounds that offer health benefits to men and women. The company was founded in 2017 and is headquartered in San Francisco, California. In June 2020, the World Economic Forum named Brightseed one of its 2020 Technology Pioneers, a distinction it bestows on companies shaping the future via their emerging technologies. Flatt, no stranger to the biosciences sector, has a 35-year track record of transforming scientific breakthroughs and advances in technology into popular health products. Prior to founding Brightseed, he was chief technology officer for Synthetic Genomics, a leader in synthetic biology. He also led R&D at Martek Biosciences and Mascoma. Flatt received his Bachelor of Science degree in chemical engineering from the Massachusetts Institute of Technology, his Master of Science degree in chemical engineering from the University of California, Berkeley, and a Doctor of Philosophy degree in chemical and biochemical engineering from the University of Wisconsin-Madison. Title: President and Chief Executive Officer William Vogel is President and Chief Executive Officer at Tollos, Inc. With over 25 years of international industry experience and a reputation for bold business transformation, Vogel brings a breadth of knowledge to Tollos. He specializes in change management, operational improvement, new business development, market realignment, and the diversification of complex enterprises. His seasoned career spans across multiple industries. His operating experience includes both corporate and private equity environments with vast expertise in a variety of areas: P&L, general management, marketing, pricing, sales, commercial operations, supply chain, and manufacturing. Vogel previously served as CEO with DMS Health Technology where he rebuilt the leadership team, formulated a new market strategy, and directed the company to a successful sale to a public strategic within 21 months. In his leadership roles with Philips Healthcare, he ran a $250 million Home Healthcare division, delivered $3 billion in equipment revenue and restructured a global change management initiative. Additionally, he developed $120 million in cumulative EBITA as an international corporate marketing leader. Vogel received his Bachelor of Science degree in mechanical engineering from Yale University and his Master of Business Administration degree from Harvard Business School. Title: Chief Executive Officer and Co-Founder Akhil Tripathi is Chief Executive Officer and Co-Founder of Signifier Medical Technologies. Tripathi is a successful serial entrepreneur and innovator in the MedTech sector, having developed and commercialized several novel medical devices, including an adjustable wheelchair, a robotic navigation system for neurosurgeries, and a spinal implant for the cervical spine. He comes from a medical device background, sits on multiple boards, and is associated with companies in the spaces of cancer treatment and robotic surgery. He is currently the CEO of Signifier Medical Technologies, which he co-founded together with Prof. Dr. Anshul Sama in 2015. Signifier Medical Technologies is a global medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with sleep disordered breathing conditions and snoring. Signifier’s proprietary therapy, eXciteOSA®, is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology that’s FDA-authorized in the U.S. for mild obstructive sleep apnea and snoring. The technology is proven safe and effective supported by clinical data from prestigious, well-recognized universities and academic institutions. Title: Chief Executive Officer Timothy Moran is the Chief Executive Officer of Motus GI Holdings, a medical technology company that specializes in endoscopy solutions associated with the diagnosis and management of gastrointestinal conditions. The company's flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device that helps facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. Motus reported a steady increase in commercial momentum during the second half of 2020 compared to the first half of the year — despite the limited access to hospitals for many people because of the ongoing pandemic. Ever since joining Motus in 2018, Moran has leveraged his broad commercial experience and leadership in the medical technology sector to drive growth for the company. He’s been responsible for leading the development of the company's short and long-term strategies, providing daily oversight, and communicating on behalf of Motus to shareholders and government agencies alike. Before Motus, Moran held roles in management and sales for over two decades at ConvaTec and Covidien. Moran also served on the CEO Advisory Council for Advanced Medical Technology Association (AdvaMed), a medical device trade association. Moran received his Bachelor of Arts degree in organizational communication at The State University of New York at Geneseo. Title: Chief Executive Officer and Co-Founder Silvia Pfeiffer is the Chief Executive Officer and Co-Founder of Coviu, a company that offers a virtual clinic configured to the needs of healthcare businesses. As Australia's largest telehealth platform, with over 300,000 sessions taking place per month, Coviu's platform enables healthcare practitioners to conduct private video consultations with patients over the internet securely. The platform also allows healthcare providers to replicate essential business operations digitally such as Medicare payments, triage, prescriptions, and a digital waiting room. As CEO and Co-Founder, Pfeiffer is a repeat entrepreneur, previously having founded the Web video analytics company Vquence. Overall, Pfeiffer has more than 20 years of experience with Web video businesses having worked in technology innovation for Google, Mozilla, NICTA, and most recently CSIRO. Coviu is the result of a CSIRO spinout bringing innovation to digital healthcare since 2015. In addition, she has published two books on HTML5 video and recently one for healthcare businesses to help them set up video consultations sustainably. She received her Master of Business Administration degree in business management and computer science as well as her Doctor of Philosophy degree in computer science from the University of Mannheim. Title: Founder and Chief Executive Officer William Brandham is the Founder and Chief Executive Officer of Pabau. He founded Pabau from a garage in Leicester in 2012. He began his career as one of two employees in the U.K., which fast expanded to over 100 employees worldwide. Pabau is a complete practice management application used by thousands of healthcare practitioners across the globe. It has clients of all sizes from large teams to solo practitioners and anything in between. From 2011 to 2020, Pabau experienced on average a 125 percent increase year on year, with this being doubled between 2020 and 2021. With the company having invested over £2.2 million into their paperless platform "Pabau Go" in January 2021, the future for Pabau looks brighter than ever, with uptake expecting to grow exponentially by the end of 2022. Prior to Pabau, Brandham was project manager and founder at Webbier Solutions, a company that delivers high quality software and e-business solutions. He was also managing director at Tickier.com, a company that integrates advanced CRM features to ensure maximum sales. Brandham received his Bachelor of Science degree in computer science from the University of Leicester, from which he won The Leicester Award for Employability in 2011. Title: Chief Executive Officer Clive van Deventer is the Chief Executive Officer of Revitalife Sleep Solutions, an Australia-based company that specializes in therapeutic beds and chairs. Their clients range from elite athletes to senior citizens. Since 2004, the company has focused on innovative technology, which has resulted in thousands of Australians suffering less from their aches, pains, and ailments. In 2019 Revitalife claimed Australia's most prestigious award in the disability care sector. The company received The Most Outstanding Therapeutic Sleep Systems Provider award at the Australian Enablement Awards, a government-backed initiative. Known for being an astute and dynamic CEO, van Deventer has had an undeniable impact on Revitalife since beginning his tenure in November of 2018. Prior to Revitalife, van Deventer was the CEO of Bartercard, one of the world’s largest trade exchange companies. Before that he held executive and sales positions at multiple companies around the globe, including Buyuo Pty Ltd., Wyndham Vacation Resorts Asia Pacific, Club Leisure Group, and Mueller Sports Medicine South Africa. Despite forgoing a traditional university experience early on in his life, in 2013 van Deventer went back to school and earned his Master of Business Administration degree from the Australian Institute of Business. Title: Founder and Chief Executive Officer Jeffrey Wessler founded Heartbeat Health in 2017 to be the world’s first telemedicine platform for cardiologists, and currently serves as Heartbeat’s Chief Executive Officer. Wessler envisioned a platform focused on the provider, that uses virtual care to bring patients through guideline-based clinical pathways and promotes long-term health and preventative care. With more than 60,000 patients using Heartbeat, he has already led the startup to break new ground in patient health and communication and best-in-class outcomes in virtual heart care. Unlike many CEOs within the healthcare technology industry, Wessler has a great deal of experience working on the front lines of medicine. He completed his medical residency and cardiology fellowship

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Metabolon

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metabolon is included in 6 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

M

Microbiome

274 items

M

Medical Devices

8,341 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

O

Omics

963 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Metabolon Patents

Metabolon has filed 64 patents.

The 3 most popular patent topics include:

  • Mass spectrometry
  • Rare diseases
  • Diabetes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/16/2018

7/13/2021

Mass spectrometry, Chromatography, Analytical chemistry, Ion source, Metabolism

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/16/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/13/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Mass spectrometry, Chromatography, Analytical chemistry, Ion source, Metabolism

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Metabolon Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Metabolon Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.